Despite proven benefits, prophylactic treatment for Hemophilia A is hampered by the short half-life of Factor VIII. A recombinant Factor VIII-Fc fusion protein (rFVIIIFc) was constructed to determine the potential for reduced frequency of dosing. rFVIIIFc has an approximately 2-fold longer half-life than rFVIII in Hemophilia A (HemA) mice and dogs. The extension of rFVIIIFc half-life requires interaction of Fc with the neonatal Fc receptor (FcRn). In FcRn knockout mice, the extension of rFVIIIFc half-life is abrogated, and is restored in human FcRn transgenic mice. The Fc fusion has no impact on FVIII specific activity. rFVIIIFc has comparable acute efficacy as rFVIII in treating tail clip injury in HemA mice; and fully corrects whole blood clotting time (WBCT) in HemA dogs immediately post-dosing. Furthermore, consistent with prolonged half-life, rFVIIIFc shows 2-fold longer prophylactic efficacy in protecting HemA mice from tail vein transection bleeding induced 24 -48 hrs after dosing. In HemA dogs, rFVIIIFc also sustains partial correction of WBCT 1.5-2 fold longer than rFVIII. rFVIIIFc was well tolerated in both species. Thus, the rescue of FVIII by Fc fusion to provide prolonged protection presents a novel pathway for FVIII catabolism, and warrants further investigation.
INTRODUCTION
Hemophilia A is an X-linked bleeding disorder caused by deficiency of factor VIII (FVIII) activity 1 . The disease is characterized by spontaneous hemorrhage and excessive bleeding after trauma. Over time, repeated bleeding into muscles and joints, which begins in early childhood, results in hemophilic arthropathy and irreversible joint damage. This damage is progressive and leads to pronounced musculoskeletal morbidity 1 . Prophylaxis significantly reduces joint damage and long-term sequelae, and improves quality of life in comparison to on-demand treatment 2, 3 . However, the short half-life (10-12 hrs) of FVIII necessitates dosing every other day or three times per week by intravenous injection for full prophylaxis 2, 4, 5 . Therefore, a longer-acting FVIII would represent a key advancement in the management of hemophilia A.
We have developed a recombinant factor VIII-Fc (rFVIIIFc) fusion protein to extend the half-life of FVIII by leveraging a naturally-occurring biologic pathway. rFVIIIFc is a heterodimeric protein comprising a single B-domain-deleted (BDD) FVIII linked recombinantly to the Fc domain of human immunoglobulin G1 (IgG1). The Fc domain enables binding to the neonatal Fc receptor (FcRn), which is responsible for protection of
IgG from degradation and facilitates its recycling 6, 7 , resulting in a half-life for IgG of approximately three weeks in humans. The Fc domain of IgG1 has been fused to growth factors, cytokines, enzymes and ligand-binding regions of receptors [8] [9] [10] ; a number of these fusion proteins have been approved as therapeutics (e.g. etanercept, abatacept, belatacept, alefacept, rilonacept, romiplostim). However, traditional dimeric Fc fusions,
For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From created through the fusion of the monomeric effector protein to a monomer of Fc and then coupled through a disulfide bond to create a dimer, were not effective for large coagulation proteins such as FVIII. Thus, we have developed methods to create novel Fc fusion protein constructs in which a single (monomeric) effector molecule is attached to Fc [11] [12] [13] . We have applied this approach to a number of proteins, including human rFIX 14 , rFVIIa 15 , and BDD rFVIII. This is the first report evaluating the pharmacokinetics and efficacy of rFVIIIFc compared to rFVIII in mouse and dog models of hemophilia A, in support of subsequent human studies.
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METHODS AND MATERIALS

Recombinant FVIII-Fc fusion protein (rFVIIIFc).
The rFVIIIFc expression plasmid pBUDCE4.1 (Invitrogen) contains two expression cassettes. One expresses, under the control of CMV promoter, native human FVIII signal sequence followed by BDD FVIII (S743 to Q1638 fusion) directly linked to the Fc region of human IgG1 (amino acids D221 to K457, EU numbering) with no intervening sequence. The other uses the EF1α promoter to express the Fc region alone with a heterologous mouse IgκB signal sequence.
Human embryonic kidney 293 cells (HEK293H, Invitrogen) were transfected with this plasmid, and a stable clonal suspension cell line was generated that expressed rFVIIIFc.
Protein was purified from defined cell culture harvest media using a three column purification process, including a FVIII-specific affinity purification step 16 followed by a combination of anion exchange and hydrophobic interaction chromatographic steps. and reconstituted according to the manufacturer's instructions.
Recombinant FVIII (rFVIII)
Recombinant
Animals
The hemophilia A (HemA) mice bearing a FVIII exon 16 knockout on a 6
The genotypes for FcRn KO mice are mFcRn (-/-) and mβ2m (-/-), and for Tg32B are mFcRn (-/-), mβ2m (-/-), hFcRn (+/+), and hβ2m (+/+). C57BL/6 mice were purchased from The Jackson Laboratories (Bar Harbor, ME 
SPR analysis of rFVIIIFc-FcRn interactions
Binding of rFVIIIFc to FcRn
The affinity of rFVIIIFc for single-chain mouse, canine, and human FcRn was evaluated using surface plasmon resonance ( Figure S1 ). The rates of association and dissociation for the complex between rFVIIIFc and mouse FcRn were much slower than those for canine and human FcRn. Half-maximal binding (EC 50 ) of rFVIIIFc to human FcRn was approximately 4-fold weaker than that to canine FcRn, and more than 20-fold weaker than that to mouse FcRn (Table 1) . Similarly, human IgG1 also showed the highest affinity to murine FcRn, while binding affinity to canine FcRn was less compared to murine FcRn, but greater compared to human FcRn (Table 1) .
FcRn-dependent improvement in pharmacokinetics of rFVIIIFc in mice
Interaction of Fc with FcRn is considered the underlying mechanism for extending half- The PK parameters ( 
Improved PK/PD of rFVIIIFc in Hemophilia A dogs
The PK and pharmacodynamics (PD) of rFVIIIFc were also studied in hemophilia A dogs. Following an intravenous dose of 125 IU/kg of rFVIIIFc, the WBCT was immediately corrected to normal, which is in the range of 8 -12 min in normal dogs ( Figures 5A and B) . The WBCT remained below 20 min, indicating FVIII activity >1%, through approximately 4 days in 3 out of 4 rFVIIIFc-treated dogs and 3 days in the remaining dog ( Figure 5A ). In dog M12 treated with 114 IU/kg of rFVIII and dog M38 with 120 IU/kg of rFVIII, the WBCT was also corrected to normal immediately after dosing. However, the WBCT remained below 20 min for 2 days in M12 and 3 days in M38, approximately 1.5 -2-fold shorter than that achieved by rFVIIIFc ( Figure 5B ).
Furthermore, both rFVIIIFc and rFVIII treatment also improved aPTT clotting time similarly at 5 min post dosing (Table S1 ).
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The PK of rFVIIIFc antigen ( Figure 6A ) was determined by measuring the concentration of rFVIIIFc in plasma with a rFVIIIFc-specific ELISA that detects both the FVIII and Fc portions of the molecule. The t 1/2 of rFVIIIFc antigen is 15.7 ± 1.7 hr (Figure 6A ), similar to the t 1/2 of rFVIIIFc activity ( Figure 6B ), as measured by the chromogenic assay: 15.4 ± 0.3 hr (Table 3 ). There is a good correlation between the FVIII activity and the rFVIIIFc antigen data, thereby demonstrating that rFVIIIFc protein was fully active in vivo.
In two of the dogs (M12 and M38) that also received a single dose of rFVIII 72 hrs prior to dosing with rFVIIIFc, the t 1/2 of rFVIII antigen was determined to be 6.9 hrs and rFVIII activity 7.4 hrs. Therefore, the plasma half-life of rFVIIIFc was approximately twice as long compared to that for rFVIII by both antigen and activity measurements.
In addition, platelet count and fibrinogen were assessed to serve as preliminary tests for thrombogenicity. After dosing with either rFVIIIFc or rFVIII, platelet numbers and plasma fibrinogen concentration did not change from pre-dose values (data not shown). . However, the finding is consistent with the observation that residues thought to bind phospholipids, ie, K2092/F2093 in C1, M2199/F2200 and L2251/L2252 in C2, all appear to form a surface that is distant from the C-terminal residues of FVIII 24, 25 .
In our studies, the half-life of rFVIIIFc was doubled only in mice expressing either endogenous murine or transgenic human FcRn, but not in FcRn KO mice ( Figure 2 and Table 2 ), demonstrating that the mechanism of prolonging half-life of rFVIIIFc is clearly mediated by FcRn. While it is known that both endothelial and hematopoietic cells contribute equally in recycling internalized IgG to the cell surface to facilitate the longevity of IgG and protection from degradation, 26, 27 it is not known specifically which Figure S1 ). ‡ Due to the high affinities, the low binding curves at low analyte concentrations did not reach equilibrium under the normal operating conditions of the instrument.
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